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Abstract
Leukocytoclastic vasculitis (LCV) is a heterogenous group of disorders that may manifest as a mild disease isolated to the skin or be a
part of life-threatening systemic vasculitis. According to the 2012 Chapel Hill Consensus Conference nomenclature, patients
presenting symptoms of LCV confined only to the skin should be defined as suffering from a single-organ cutaneous small vessel
vasculitis (SoCSVV). SoCSVV is a benign disease with a good clinical outcome but with a significant risk of relapse and skin ulcer
formation.
The aim of the current study was to characterize SoCSVV and to identify factors that may be associated with the risk of recurrence
and skin ulcers.
Medical records of patients with LCV hospitalized at the Department of Dermatology at University Hospital in Cracow in the years
2010 to 2015 were analyzed.
A total of 24 patients fulfilled criteria of SoCSVV. Drugs and preceding infections were identified as precipitating factors in 40% and
20% of cases, respectively. Skin lesions other than palpable purpura (i.e., macules, urticarial vasculitis, or ulcers) were identified in
almost half of the patients. Interestingly, the presence of macules independently increased the risk of skin ulcer formation (odds
ratio=16; 95% confidence interval: 1.5–176.6; P=0.0075) in the multivariate logistic regression analysis. One-quarter of patients
with SoCSVV experienced relapse during the 6-month follow-up. The greater number of affected skin areas was an independent risk
factor of recurrence (odds ratio=5; 95% confidence interval: 2–45; P=0.02).
SoCSVV was usually associated with drugs and preceding infections. The disease relapses in approximately one-quarter of the
patients. The more severe the skin involvement in the course of SoCSVV, the higher is the risk of recurrence.
Abbreviations: CHCC = Chapel Hill Consensus Conference, CRP = C-reactive protein, LCV = leukocytoclastic vasculitis,
SoCSVV = single-organ cutaneous small vessel vasculitis.
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1. Introduction
Leukocytoclastic vasculitis (LCV) is a disorder characterized by
skin lesions and typical histological features (i.e., neutrophilic
inflammation predominantly limited to the superficial cutaneous
venules, leukocytoclasia, fibrinoid necrosis, and erythrocyte
extravasation into the vessel wall). The condition can be induced
by a variety of causes, including drugs, infections, connective
tissue diseases, and malignances.[1] However, in most cases it is
idiopathic. LCV shows manifestations ranging from a mild
disease isolated to the skin to the symptoms of severe systemic
vasculitis.[1]
In 2012, a revised nomenclature of vasculitides was introduced
at the International Chapel Hill Consensus Conference
(CHCC).[2] One of the changes includes the recognition of a
novel entity—“single-organ vasculitis”—for vasculitides affect-
ing the vessels in a single organ with no features suggesting
involvement of other organs. When the disease is confined to the
skin, the term single-organ cutaneous small vessel vasculitis
(SoCSVV) should be used.[2]
Data regarding clinical characteristics, causes, prognosis, and the
rate of relapse of SoCSVV are currently lacking. Until now, only 2
studies on the SoCSVV showed that the disease seems to be a mild,
self-limiting condition with a good clinical outcome. However, the
authors emphasized that the relapse rate seems to be significant,
sometimes causing problems in everyday clinical practice.[3,4]
Moreover, some patients with palpable purpura may later develop
ulcers that significantly lengthen the durationof treatment andmay
be further complicated by infections or scarring.
The aim of the current study was to clinically characterize the
group of patients with SoCSVV, and determine factors that may
influence the recurrences and ulcer formation.
2. Patients and methods
2.1. Patient population
Medical records of adult patients (aged >20 years) diagnosed
with LCV and hospitalized in the Department of Dermatology at
University Hospital in Cracow in the years 2010 to 2015 were
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reviewed. The study has been reviewed and approved by the
Cracow University Hospital Institutional Review Board.
2.2. Clinical study and clinical definitions
Full blood cell count, coagulation, liver and renal function tests,
urinalysis, erythrocyte sedimentation rate, C-reactive protein
(CRP), hepatitis B, C, and HIV serology, antinuclear antibody,
antineutrophil cytoplasmic antibodies, complement levels (C3,
C4), streptococcal antibodies, chest radiography, abdomen
ultrasound examination, stool guaiac tests, and skin biopsy
were performed in all patients.
The diagnosis of SoCSVV was based on the presence of typical
nonthrombocytopenic palpable purpura; a skin biopsy showing
characteristic histological findings such as neutrophilic inflam-
mation, leukocytoclasia, fibrin deposits, and erythrocyte extrav-
asation into the vessel wall; and no signs, symptoms, and
laboratory findings consistent with involvement of other than
skin organs. Other than palpable purpura lesions on the skin,
were diagnosed by the board certified-dermatologist. There were
macules (flat, nonpalpable, circumscribed, red lesions), ulcers (a
deep defect of the skin, with loss of at least the entire epidermis
plus superficial dermis), and urticarial vasculitis (urticarial
plaques lasting >24 hours with neutrophils infiltrating vessels’
walls in histopathological examination).
A drug or infection process (usually an upper respiratory
tract infection) was considered as the probable precipitating
event if it was taken or occurred within a week before the onset
of the skin lesions. When a patient developed SoCSVV after
antibiotic or symptomatic treatment for a mild infection, both
the infection and the drug were considered as possible
precipitating events.
2.3. Data collection and statistical analysis
Clinical and laboratory data were extracted from patients’
clinical records according to a specifically designed protocol,
reviewed to confirm the diagnosis, and stored in a computer-
ized file. To minimize entry error, all data were double-
checked. Statistical analysis was performed with the STATIS-
TICA 7.1 PL software package (StatSoft Inc, Tulsa, OK). If not
stated otherwise, data were expressed as median and
minimum–maximum values. Continuous variables were com-
pared with the Mann–Whitney U test. The x2 test or the Fisher
exact test was used for the dichotomous variables. To identify
independent factors, a multivariate logistic regression analysis
was used. A P value <0.05 was considered statistically
significant.
3. Results
Among 30 patients with LCV, 24 fulfilled criteria of SoCSVV.
Palpable purpura was present in all patients. However, other skin
lesions were also found: red macules, urticarial vasculitis, and
ulcers (Table 1). With regard to potential precipitating factors, a
history of drugs and preceding infection was identified in almost
half of the patients (Table 1). All patients were negative for
hepatitis B, C, and HIV serology. In none of individuals were
identified either antinuclear antibodies or antineutrophil cyto-
plasmic antibodies. In all patients complement levels were in
normal range.
The clinical outcome in all patients was good. Symptoms
resolved in almost 80% of individuals. Among all the included
patients, 9 (37.5%) were treated with systemic steroids. When
compared to those with supportive treatment only, they had
significantly higher white blood cell count and CRP levels (9 vs.
7.12103/mL, 11.8 vs. 7.25mg/dL, respectively; P<0.05).
Interestingly, there were no significant differences found between
group treated and not with systemic steroids with respect to the
type of skin lesions, number of affected body skin areas, and
other clinical and laboratory results (data not shown).
After a median follow-up of 6 months, relapses occurred in
25% of patients with SoCSVV. Clinical course of relapse was
similar to that observed at the first episode (regarding the type
and localization of skin lesions and blood laboratory findings).
We did not find any association between relapses and the type of
treatment (i.e., antibiotics and/or steroids). Interestingly, howev-
er, patients with a higher number of affected skin areas at the first
episode were at a higher risk of relapse (odds ratio=5; 95%
confidence interval: 2–45; P=0.02).
Occurrence of skin ulcers significantly lengthens the hospitali-
zation time (P<0.05). Skin ulcers were positively correlated with
red macules, higher number of localizations, and longer duration
of skin lesions before admission to the hospital (P<0.05). The
multivariate logistic regression analysis revealed that macules
independently increased the risk of skin ulcers (odds ratio=16;
95% confidence interval: 1.5–176.6; P=0.0075).
Table 1
Characteristics of patients with single-organ cutaneous small-
vessel vasculitis (SoCSVV; n=24).
Age, y (minimum–maximum) 50 (18–83)
Women, n (%) 11 (45.8)
Diabetes, n (%) 3 (12.5)
Skin lesions
Palpable purpura, n (%) 24 (100)
Red macules, n (%) 8 (33.3)
Urticarial vasculitis, n (%) 1 (4.2)
Ulcers, n (%) 4 (16.7)
Localization of skin lesions
Lower limbs, n (%) 24 (100)
Upper limbs, n (%) 8 (33.3)
Trunk, n (%) 4 (16.7)
Duration, d (minimum–maximum) 21 (1–600)
Blood laboratory findings
WBC, 103mL1 (minimum–maximum) 7.2 (3.6–30.7)
Neutrophils, 103mL1 (minimum–maximum) 4.0 (1.8–22.0)
Lymphocytes, 103mL1 (minimum–maximum) 2.4 (1.3–5.2)
Eosinophils, 103mL1 (minimum–maximum) 0.2 (0.07–0.62)
CRP, mg/dL (minimum–maximum) 11.8 (5.0–77.4)
PLT, 103mL1 (minimum–maximum) 221 (174–413)
aPTT, s (minimum–maximum) 29.6 (22–34.9)
INR (minimum–maximum) 1.1 (1.03–1.3)
Creatinine, mmol/L (minimum–maximum) 72 (48–106)
ALT, IU/L (minimum–maximum) 25 (15–87)
AST, IU/L (minimum–maximum) 27 (13–54)
Cause
Infection, n (%) 8 (33.3)
Drugs, n (%) 4 (16.7)
Infections+drugs, n (%) 1 (4.2)
Treatment
GCS, n (%) 9 (37.5)
Antibiotics, n (%) 8 (33.3)
Relapses, n (%) 6 (25)
Data are presented as median (minimum–maximum) or otherwise stated. ALT = alanine
aminotransferase, aPTT = activated partial thromboplastin time, AST = aspartate aminotransferase,
CRP = C-reactive protein, GCS = glucocorticoids, INR = international normalized ratio, PLT =
platelets, WBC = white blood cell count.
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4. Discussion
Following the 2012 CHCC definitions, SoCSVV is considered a
vasculitis affecting the skin without the involvement of the vessels
in any other organ. Therefore, only a few patients with LCV
would fulfill the SoCSVV criteria.[2]
SoCSVV is usually a benign disease with a good clinical
outcome. However, our observations indicate that it frequently
relapses, increasing healthcare costs and patients’ concerns. In the
current study, we have shown clinical characteristics of patients
with SoCSVV with special emphasis on the identification of
factors related to their recurrence.
The etiology of SoCSVV is unknown. Recently, it has been
shown that drugs and mild infections such as upper respiratory
tract infections are responsible for 25% and 10% of SoCSVV,
respectively.[3,4] In our study these frequencies were a little
different with more infections (33.3%) than drugs (16.7%) as
causal agents of SoCSVV.
The main clinical feature of every LCV, including SoCSVV, is
palpable purpura. However, other skin lesions, such as red
macules, urticaria vasculitis, and ulcers, may be observed.[3,4] In
our series, red macules were identified as the second most
common clinical finding in patients with SoCSVV. Interestingly,
in a multivariate logistic regression analysis, we identified
macules as an independent factor of ulcers’ occurrence in the
course of vasculitis. Further studies are needed to establish
whether early and more aggressive treatment (systemic steroids)
in individuals with macules and SoCSVV may prevent ulcer
formation.
Most SoCSVV patients have a single episode that resolves
within a few weeks. However, in some patients relapses occur. In
our study, the frequency of recurrence has been assessed at 25%,
higher than previously reported (∼10%).[3]
In almost all cases of SoCSVV palpable purpura is localized on
the lower extremities. In one-third of our patients we found skin
lesions also on the upper limbs, and almost one-fifth had them on
the trunk. Interestingly, ahighernumberof affected skin areaswere
strongly associated with the risk of relapse. We may only
hypothesize that the higher number of sites with skin involvement
may reflect a more advanced disease with more pronounced levels
of circulating immune complexes and antibodies. However, we
could notfindany correlationbetween the number of sites involved
and the levels of serum inflammatory markers measured.
Finally, we tried to asses factors that may have influenced the
method of treatment of SoCSVV (supportive treatment vs.
systemic steroids). In both such defined groups, we did not find
any differences in clinical features. However, patients treated
with steroids had higher white blood cell count and CRP levels.
This was certainly not the only reason to opt for systemic steroid
therapy. Presumably, the therapeutic decisions were based rather
on the individual experience of the physician.
One of the most important limitations of this study is a small
number of patients. The incidence of LCV is unknown, but the
disorder is presumed to be uncommon. Thus, there is a need for
multicentered studies or meta-analysis including small studies
(such as ours). Second, according to the study protocol, only
hospitalized patients were included in the study. It could cause a
selection bias due to the recruitment of mostly more severe cases.
In conclusion, according to the 2012 CHCC definitions,
SoCSVV should be differentiated from other LCV. SoCSVV is a
benign form of vasculitis confined to the skin. Careful clinical and
laboratory assessment is highly recommended in every patient
presenting with the skin manifestations of LCV (i.e., palpable
purpura) to exclude systemic involvement. In systemic vasculitis
prognosis and treatment substantially differ. SoCSVV is
commonly associated with drugs and/or infections with a risk
of ulcer formation and relapses. The risk of recurrences seems to
be correlated with a higher number of affected skin sites. Macules
as additional skin findings in patients with SoCSVV may be the
prognostic factor of ulcer formation that may occur in the course
of vasculitis.
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